重组人干扰素α-1b联合布地奈德治疗支气管肺炎患儿的效果及安全性分析

Effect and safety analysis of recombinant human interferon alpha-1b combined budesonide in children with bronchopneumonia

目的探讨重组人干扰素α-1b联合布地奈德治疗支气管肺炎患儿的效果及安全性。方法选取2019年5月至2019年12月本院收治的80例支气管肺炎患儿为研究对象,随机分为参照组与研究组,各40例。参照组实施常规治疗,研究组实施重组人干扰素α-1b联合布地奈德治疗。比较两组患儿的治疗效果、症状积分、症状消失时间、不良反应。结果研究组治疗有效率高于参照组(P<0.05)。治疗后,研究组症状积分优于参照组(P<0.05);研究组症状消失时间短于参照组(P<0.05)。两组患者不良反应发生率比较差异无统计学意义。结论支气管肺炎患儿采用重组人干扰素α-1b联合布地奈德治疗,可缓解症状,促进恢复,不良反应少,安全性高,治疗效果显著。

Objective To investigate the efficacy and safety of recombinant human interferon alpha-1b combined budesonide in the treatment of children with bronchopneumonia.Methods A total of 80 children with bronchopneumonia admitted to our hospital from May 2019 to December 2019 were selected as the research subjects.They were randomly divided into reference group and study group,with 40 cases in each group.The reference group underwent routine treatment and the study group underwent recombinant human interferonα-1b combination budesonide treatment.The treatment effect,symptom score,symptom disappearance time,adverse reaction were compared between the two groups of children.Results The effective rate of the study group was higher than that of the reference group(P<0.05).After treatment,the symptom score of the study group was better than that of the reference group(P<0.05).The time of symptom disappearance in the study group was shorter than that in the reference group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Recombinant human interferon alpha-1b combined with budesonide can relieve symptoms,promote recovery,and has less adverse reactions,high safety and remarkable therapeutic effect.